메뉴 건너뛰기




Volumn 3, Issue 3, 2013, Pages

Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: Evidence from a meta-analysis of 2334 patients from 5 randomised trials

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE;

EID: 84877648468     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001802     Document Type: Article
Times cited : (47)

References (28)
  • 1
    • 52649180045 scopus 로고    scopus 로고
    • Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective
    • Alonso A, Molenberghs G. Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective. Stat Methods Med Res 2008;17:497-504.
    • (2008) Stat Methods Med Res , vol.17 , pp. 497-504
    • Alonso, A.1    Molenberghs, G.2
  • 2
    • 52649123777 scopus 로고    scopus 로고
    • Two simple approaches for validating a binary surrogate endpoint using data from multiple trials
    • Baker SG. Two simple approaches for validating a binary surrogate endpoint using data from multiple trials. Stat Methods Med Res 2008;17:505-14.
    • (2008) Stat Methods Med Res , vol.17 , pp. 505-514
    • Baker, S.G.1
  • 3
    • 52649101507 scopus 로고    scopus 로고
    • Surrogate endpoints: Wishful thinking or reality?
    • Burzykowski T. Surrogate endpoints: Wishful thinking or reality? Stat Methods Med Res 2008;17:463-6.
    • (2008) Stat Methods Med Res , vol.17 , pp. 463-466
    • Burzykowski, T.1
  • 4
    • 52649122745 scopus 로고    scopus 로고
    • Use of progression-free survival as a surrogate marker in oncology trials: Some regulatory issues
    • Chakravarty A, Sridhara R. Use of progression-free survival as a surrogate marker in oncology trials: Some regulatory issues. Stat Methods Med Res 2008;17:515-18.
    • (2008) Stat Methods Med Res , vol.17 , pp. 515-518
    • Chakravarty, A.1    Sridhara, R.2
  • 5
    • 52649149158 scopus 로고    scopus 로고
    • Surrogate endpoint validation: Statistical elegance versus clinical relevance
    • Green EM, Yothers G, Sargent DJ. Surrogate endpoint validation: Statistical elegance versus clinical relevance. Stat Methods Med Res 2008;17:477-86.
    • (2008) Stat Methods Med Res , vol.17 , pp. 477-486
    • Green, E.M.1    Yothers, G.2    Sargent, D.J.3
  • 6
    • 52649088322 scopus 로고    scopus 로고
    • Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective
    • Grothey A. Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective. Stat Methods Med Res 2008;17:529-35.
    • (2008) Stat Methods Med Res , vol.17 , pp. 529-535
    • Grothey, A.1
  • 7
    • 52649120836 scopus 로고    scopus 로고
    • Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer
    • Hughes MD. Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer. Stat Methods Med Res 2008;17:487-95.
    • (2008) Stat Methods Med Res , vol.17 , pp. 487-495
    • Hughes, M.D.1
  • 8
    • 52649094924 scopus 로고    scopus 로고
    • Surrogate endpoints for overall survival in advanced colorectal cancer: A clinician's perspective
    • Piedbois P, Croswell JM. Surrogate endpoints for overall survival in advanced colorectal cancer: A clinician's perspective. Stat Methods Med Res 2008;17:519-27.
    • (2008) Stat Methods Med Res , vol.17 , pp. 519-527
    • Piedbois, P.1    Croswell, J.M.2
  • 9
    • 52649148610 scopus 로고    scopus 로고
    • Individual-and trial-level surrogacy in colorectal cancer
    • Buyse M, Burzykowski T, Michiels S, et al. Individual-and trial-level surrogacy in colorectal cancer. Stat Methods Med Res 2008;17:467-75.
    • (2008) Stat Methods Med Res , vol.17 , pp. 467-475
    • Buyse, M.1    Burzykowski, T.2    Michiels, S.3
  • 11
    • 42949145995 scopus 로고    scopus 로고
    • Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
    • Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008;26:1987-92.
    • (2008) J Clin Oncol , vol.26 , pp. 1987-1992
    • Burzykowski, T.1    Buyse, M.2    Piccart-Gebhart, M.J.3
  • 13
    • 0346796317 scopus 로고    scopus 로고
    • Docetaxel (D) versus vinorelbine-cisplatin (VC) as front-line treatment for patients with advanced non-small cell lung cancer (NSCLC) and with a normal level of serum alpha 1 acid glycoprotein (AAG): Additional data on quality of life (QOL). Preliminary results
    • [Abstract 2680]
    • Monnier A, Zatloukal P, Siffnerova H, et al. Docetaxel (D) versus vinorelbine-cisplatin (VC) as front-line treatment for patients with advanced non-small cell lung cancer (NSCLC) and with a normal level of serum alpha 1 acid glycoprotein (AAG): Additional data on quality of life (QOL). Preliminary results. Proc Am Soc Clin Oncol 2003 [Abstract 2680].
    • (2003) Proc Am Soc Clin Oncol
    • Monnier, A.1    Zatloukal, P.2    Siffnerova, H.3
  • 20
    • 84877638088 scopus 로고    scopus 로고
    • Meta-analysis comparing docetaxel and vinca-alkaloids in the first-line treatment of NSCLC. Comparison of results based on individual patient data, study report data, and published data
    • Abstract 4
    • Laporte S, Buyse M, Baroux N, et al. Meta-analysis comparing docetaxel and vinca-alkaloids in the first-line treatment of NSCLC. Comparison of results based on individual patient data, study report data, and published data. Eur J Cancer Suppl. 2007;1:Abstract 4.
    • (2007) Eur J Cancer Suppl. , vol.1
    • Laporte, S.1    Buyse, M.2    Baroux, N.3
  • 21
    • 0035648331 scopus 로고    scopus 로고
    • Validation of surrogate endpoints in multiple randomized clinical trials with failure-time end points
    • Burzykowski T, Molenberghs G, Buyse M, et al. Validation of surrogate endpoints in multiple randomized clinical trials with failure-time end points. J R Stat Soc C 2001;50:405-22.
    • (2001) J R Stat Soc C , vol.50 , pp. 405-422
    • Burzykowski, T.1    Molenberghs, G.2    Buyse, M.3
  • 22
    • 33748751897 scopus 로고    scopus 로고
    • Surrogate threshold effect: An alternative measure for meta-analytic surrogate endpoint validation
    • DOI 10.1002/pst.207
    • Burzykowski T, Buyse M. Surrogate threshold effect: An alternative measure for meta-analytic surrogate endpoint validation. Pharm Stat 2006;5:173-86. (Pubitemid 44400217)
    • (2006) Pharmaceutical Statistics , vol.5 , Issue.3 , pp. 173-186
    • Burzykowski, T.1    Buyse, M.2
  • 24
    • 70249130544 scopus 로고    scopus 로고
    • Duration of chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis of randomized trials
    • Soon YY, Stockler MR, Askie LM, et al. Duration of chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis of randomized trials. J Clin Oncol 2009;27:3277-83.
    • (2009) J Clin Oncol , vol.27 , pp. 3277-3283
    • Soon, Y.Y.1    Stockler, M.R.2    Askie, L.M.3
  • 25
    • 71549143528 scopus 로고    scopus 로고
    • Detecting and overall survival benefit that is derived from progression-free survival
    • Broglio KR, Berry DA. Detecting and overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009;101:1642-9.
    • (2009) J Natl Cancer Inst , vol.101 , pp. 1642-9
    • Broglio, K.R.1    Berry, D.A.2
  • 26
    • 33747844588 scopus 로고    scopus 로고
    • Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: A meta-analysis
    • DOI 10.1016/S1470-2045(06)70800-2, PII S1470204506708002
    • Johnson KR, Ringland C, Stodkes BJ, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: A meta-analysis. Lancet Oncol 2006;7:741-6. (Pubitemid 44283658)
    • (2006) Lancet Oncology , vol.7 , Issue.9 , pp. 741-746
    • Johnson, K.R.1    Ringland, C.2    Stokes, B.J.3    Anthony, D.M.4    Freemantle, N.5    Irs, A.6    Hill, S.R.7    Ward, R.L.8
  • 27
    • 80051550048 scopus 로고    scopus 로고
    • Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis
    • Amit O, Mannino F, Stone AM, et al. Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis. Eur J Cancer 2011;47:1772-8.
    • (2011) Eur J Cancer , vol.47 , pp. 1772-1778
    • Amit, O.1    Mannino, F.2    Stone, A.M.3
  • 28
    • 78649478110 scopus 로고    scopus 로고
    • Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
    • Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol 2010;21:2324-32.
    • (2010) Ann Oncol , vol.21 , pp. 2324-2332
    • Soria, J.C.1    Massard, C.2    Le Chevalier, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.